Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Biotechnology company broadens supply agreement with healthcare corporation
August 4th, 2005
Morphotek, Inc., announced that it has broadened its manufacturing supply agreement with Baxter Healthcare Corporation to support the development and manufacture of its therapeutic antibody pipeline. The extended agreement will reserve capacity for manufacturing of Morphotek's lead compound MORAb-003, which is in phase I clinical trials for ovarian cancer at Memorial Sloan Kettering. This is in addition to current manufacturing for MORAb-009, which is being developed for pancreatic cancer and MORAb-004, which targets a proprietary antigen whose expression is restricted to the cell surface of embryonic endothelia cells of vessels associated with neovascular...
Source: Women's Health Weekly (2005-08-04)
|
